Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease

被引:38
作者
Bucolo, Claudio [1 ,2 ]
Fidilio, Annamaria [1 ]
Fresta, Claudia Giuseppina [1 ]
Lazzara, Francesca [1 ]
Platania, Chiara Bianca Maria [1 ]
Cantarella, Giuseppina [1 ]
Di Benedetto, Giulia [1 ]
Burgaletto, Chiara [1 ]
Bernardini, Renato [1 ]
Piazza, Cateno [3 ]
Barabino, Stefano [4 ]
Drago, Filippo [1 ,2 ]
机构
[1] Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, Catania, Italy
[2] Univ Catania, Ctr Res Ocular Pharmacol CERFO, Catania, Italy
[3] Univ Catania Consortium Unifarm, Analyt Dept, Catania, Italy
[4] Univ Milan, Ocular Surface & Dry Eye Ctr, Osped L Sacco, Milan, Italy
来源
FRONTIERS IN PHARMACOLOGY | 2019年 / 10卷
关键词
dry eye disease; inflammation; cornea; hydrocortisone; Sjogren syndrome; NF-KAPPA-B; TEAR FILM; TRAIL; CORTICOSTEROIDS; PROLIFERATION; MODELS; ROLES; TESTS; CELLS;
D O I
10.3389/fphar.2019.01240
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To investigate the ocular pharmacological profile of hydrocortisone (HC) using in vitro and in vivo models of dry eye disease. Rabbit corneal epithelial cells (SIRCs) were used to assess the effect of HC in two paradigms of corneal damage: hyperosmotic stress and scratch-wound assay. Dry eye was induced in albino rabbits by topical administration of atropine sulfate or by injection of concanavalin A (ConA) into the lacrimal gland. TNF alpha, TNF-related apoptosis-inducing ligand (TRAIL), IL-1 beta, and IL-8 were determined by ELISA or western blot in a corneal damage hyperosmotic in vitro model, with or without HC treatment. Inflammatory biomarkers, such as TNF alpha, IL-8, and MMP-9, were evaluated in tears of rabbit eye injected with ConA and treated with HC. Tear volume and tear film integrity, in both in vivo models, were evaluated by the Schirmer test and tear break-up time (TBUT). Ocular distribution of four formulations containing HC (0.001%, 0.003%, 0.005%, and 0.33%) was performed in the rabbit eye. Aqueous humor samples were collected after 15, 30, 60, and 90 min from instillation and then detected by LC-MS/MS. Hyperosmotic insult significantly activated protein expression of inflammatory biomarkers, which were significantly modulated by HC treatment. HC significantly enhanced the re-epithelialization of scratched SIRCs. Treatment with HC eye drops significantly reduced the tear concentrations of TNF-alpha, IL-8, and MMP-9 vs. vehicle in the ConA dry eye model. Moreover, HC significantly restored the tear volume and tear film integrity to levels of the control eyes, both in ConA- and atropine-induced dry eye paradigms. Finally, we demonstrated that HC crossed, in a dose-dependent manner, the corneal barrier when the eyes were topically treated with HC formulations (dose range 0.003-0.33%). No trace of HC was detected in the aqueous humor after ocular administration of eye drops containing the lowest dose of the drug (0.001%), indicating that, at this very low concentration, the drug did not pass the corneal barrier avoiding potential side effects such as intraocular pressure rise. Altogether, these data suggest that HC, at very low concentrations, has an important anti-inflammatory effect both in vitro and in vivo dry eye paradigms and a good safety profile.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Therapeutic benefits of glycerol in dry eye disease
    Ronderos, Victoria
    Bollag, Wendy B.
    FRONTIERS IN MEDICINE, 2025, 11
  • [32] Resveratrol for dry eye disease - Hope or Hype?
    Shetty, Rohit
    Joshi, Parth D.
    Mahendran, Krithikaa
    Jayadev, Chaitra
    Das, Debashish
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2023, 71 (04) : 1270 - 1275
  • [33] Review: MicroRNAs in ocular surface and dry eye diseases
    Rassi, Diane Meyre
    De Paiva, Cintia S.
    Dias, Lara Cristina
    Modulo, Carolina Maria
    Adriano, Leidiane
    Fantucci, Marina Zilio
    Rocha, Eduardo Melani
    OCULAR SURFACE, 2017, 15 (04) : 660 - 669
  • [34] Effectiveness of a New Active Tear Substitute Containing 0.2% Hyaluronic Acid and 0.001% Hydrocortisone on Signs and Symptoms of Dry Eye Disease by Means of Low- and High-Tech Assessments
    Paolo Fogagnolo
    Giuseppe Giannaccare
    Rita Mencucci
    Edoardo Villani
    Vincenzo Orfeo
    Pasquale Aragona
    Ophthalmology and Therapy, 2024, 13 : 251 - 266
  • [35] Ocular Surface Epithelial Thickness Evaluation in Dry Eye Patients: Clinical Correlations
    Liang, Qingfeng
    Liang, Hong
    Liu, Hanruo
    Pan, Zhiqiang
    Baudouin, Christophe
    Labbe, Antoine
    JOURNAL OF OPHTHALMOLOGY, 2016, 2016
  • [36] Effectiveness of a New Active Tear Substitute Containing 0.2% Hyaluronic Acid and 0.001% Hydrocortisone on Signs and Symptoms of Dry Eye Disease by Means of Low- and High-Tech Assessments
    Fogagnolo, Paolo
    Giannaccare, Giuseppe
    Mencucci, Rita
    Villani, Edoardo
    Orfeo, Vincenzo
    Aragona, Pasquale
    Italian Dry Eye Study Grp, Valentino
    De Ruvo, Valentino
    Strianese, Alfonso
    Quisisana, Chiara
    Borselli, Massimiliano
    Rossi, Costanza
    Scalzo, Giovanna Carnovale
    Postorino, Elisa Imelde
    Azzaro, Claudia
    Mercuri, Stefano
    Lucarelli, Flavia
    De Vitto, Chiara
    Ferioli, Eleonora
    Marelli, Luca
    Napolitano, Pasquale
    Gianni, Mario Cristian
    Parise, Simona
    OPHTHALMOLOGY AND THERAPY, 2024, 13 (01) : 251 - 266
  • [37] Contact lenses in dry eye disease and associated ocular surface disorders
    Chaudhary, Simmy
    Ghimire, Deepak
    Basu, Sayan
    Agrawal, Vinay
    Jacobs, Deborah S.
    Shanbhag, Swapna S.
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2023, 71 (04) : 1142 - 1153
  • [38] Macrophage Phenotype in the Ocular Surface of Experimental Murine Dry Eye Disease
    In-Cheon You
    Terry G. Coursey
    Fang Bian
    Flavia L. Barbosa
    Cintia S. de Paiva
    Stephen C. Pflugfelder
    Archivum Immunologiae et Therapiae Experimentalis, 2015, 63 : 299 - 304
  • [39] Macrophage Phenotype in the Ocular Surface of Experimental Murine Dry Eye Disease
    You, In-Cheon
    Coursey, Terry G.
    Bian, Fang
    Barbosa, Flavia L.
    de Paiva, Cintia S.
    Pflugfelder, Stephen C.
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2015, 63 (04) : 299 - 304
  • [40] Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease
    Valdes-Arias, David
    Locatelli, Elyana V. T.
    Sepulveda-Beltran, Paula A.
    Mangwani-Mordani, Simran
    Navia, Juan Carlos
    Galor, Anat
    DRUGS, 2024, 84 (05) : 549 - 563